Mode
Text Size
Log in / Sign up
N/A N=124 Randomized Single-blind Treatment

The Post-Operative Pain Management of Pediatric Supracondylar Elbow Fractures

Elbow Fracture

Enrolled (actual)
124
Serious AEs
0.0%
Results posted
Jun 2012
Primary outcome: Primary: The Faces Pain Scale-Revised (FSP-R) Scores (Scored 0-10). — 4.14; 2.73; 3.66 Scores on a scale — p=0.074

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Oxycodone with Acetaminophen (Drug); Bupivacaine 0.25% (Drug); Ropivacaine 0.20% (Drug)
Age
Pediatric · 4+ yrs
Sex
All
Sponsor
University of Colorado, Denver
Primary completion
Aug 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
The Faces Pain Scale-Revised (FSP-R) Scores (Scored 0-10).
4.14; 2.73; 3.66 0.074
SECONDARY
Total Quality Pain Management Survey (TQPM) Scores for Questions # 16: Child's Current Level of Pain, Question # 17: Child's Worst Level of Pain When Moving Around After Surgery and Question # 18: Child's Worst Level of Pain While Resting
4.58; 2.73; 4.32 0.014 sig
SECONDARY
Time (in Minutes) to First Narcotic Administration
30; 50.5; 34 0.005 sig
SECONDARY
Total Dosage in Morphine Equivalents (mg/kg) of All Analgesics Received in Prior to Discharge
0.09; 0.05; 0.08 0.008 sig
SECONDARY
Need for IV Morphine of Fentanyl
19; 4; 15 0.004 sig

Summary

The goal of this study is to compare different ways of treating pain after surgery. This research study involves subjects who have a supracondylar elbow fracture and need surgery. This type of fracture occurs when the humerus (upper arm bone) is broken just above the elbow. Like any other surgery, you can expect that you will feel pain in the hours or days after the operation. Currently, despite the common occurrence of this surgery, there is not a standard way to treat and or prevent any of the pain afterwards. At this hospital, oral (take by mouth) pain medicine is commonly used to treat pain after this surgery. In this study, pain will be treated in one of the following ways: 1. with oral pain medication 2. with oral pain medicine and an intraarticular shot (a shot into the elbow joint) of bupivacaine (a "numbing" drug) or 3. with oral pain medicine and an intraarticular shot of ropivacaine (another "numbing" drug). The shots will be given during surgery. Your participation will help us find out which of these three pain control methods works the best. The correct dosages of all drugs will be safely prescribed by the doctor on an individual basis and all drugs will be used under the careful watch of your attending physician. All the drugs used this study are approved by the FDA for use in adults but they are not specifically approved for use in children. However, nearly 7 out of every 10 drugs approved for adults are not specifically approved by the FDA for use in children. All drugs used in this study will be used in a way that is considered to be safe and reasonable by the Children's Hospital.

Eligibility Criteria

Inclusion Criteria

  • ASA class I, II or III
  • Patients 4-12 years old requiring general anesthesia for closed reduction and percutaneous pinning (CRPP) of supracondylar type elbow fractures (SCEFx).
  • Patients able to understand and report their pain with the Faces Pain Scale Revised

Exclusion Criteria

  • Medical contraindications to analgesic therapy.
  • Known allergy or sensitivity to analgesic agent.
  • Clinical evidence of skin inflammation precluding the 'clean' area at the site of injection.
  • Patients lacking the cognitive understanding to report their pain with the FSP-R (unable to complete seriation task).
  • Patients necessitating open reduction due to inability to obtain an acceptable closed reduction.
  • Comorbid diagnosis of other traumatic injury that causes any local and or global pain.
  • Patients presenting to ER with neurovascular injury or compartment syndrome due to fracture.
  • For patients in either of the two intervention arms, if after three attempts, the intraarticular injection is not successful, the patient will be dropped from the study.
  • Patients admitted for complications directly related to the surgery will be dropped from analysis. Any such event will be immediately reported to COMIRB with in five business days. However, patients admitted due to a late afternoon/evening surgery and patients admitted for standard observational purposes unrelated to surgical complications, will not be dropped from the study.
  • Known drug allergy to oxycodone and or acetaminophen.
  • Children 4-7 years old weighing less than 14 kg (Weight exclusion criteria is based on a 4 year old female that is below the fifth percentile for weight, per the Center for Disease Control Growth Charts).
  • Children 8-12 years old weighing less than 20 kg (Weight exclusion criteria based on an 8 year old female that is below the fifth percentile for weight, per the Center for Disease Control Growth Charts).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01328782). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search